Episode 2 · 37 min
The Right to Try program, explained
Vince LiguoriBiotech executive, CEO of L2 Bio and Ageless Biotech
Vince Liguori explains Right to Try, the federal pathway that lets a patient with a potentially life-threatening condition use an investigational product once it has reached at least a phase 2 trial that is active and listed on ClinicalTrials.gov. He sets it apart from Expanded Access, which needs FDA approval for each request, and discloses that he is affiliated with two phase 2 trials, in knee osteoarthritis and Crohn’s disease.
He walks through what the physician has to do: confirm the product qualifies, use a sound informed consent (ideally from the manufacturer), keep the records, explain the approved treatments and their side effects, and look at whether a clinical trial is realistic for the patient. Only an MD or DO can start treatment, with nurse practitioners and PAs helping under their state’s supervision rules, and the drug itself cannot be marked up, though the services around it can be charged for.
Reporting is mandatory, covering serious adverse events and outcomes but no personal health information. Vince and Robert discuss how that data can show manufacturers and the FDA new uses and risks, and close on MedBridge Global’s free three-hour CME course on Right to Try.
Watch on YouTubeIn this episode
- Welcome
- What Right to Try is
- Which products qualify
- Right to Try and Expanded Access
- What the physician has to do
- Informed consent and records
- Approved treatments and clinical trials first
- No markup on the drug
- MDs, DOs and the care team
- Mandatory reporting
- What the data tells manufacturers
- New uses found along the way
- What to weigh before using it
- How the FDA may use the data
- Final advice for physicians
- The free Right to Try course
